Soft Tissue Sarcoma Clinical Trial
Official title:
A Phase II Study of Postoperative Radiotherapy With Tyrosine Kinase Inhibitor (Anlotinib) for Resectable Soft Tissue Sarcoma With High Recurrence Risk
NCT number | NCT05602415 |
Other study ID # | RJ2019-200 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | November 2022 |
Est. completion date | May 2024 |
Verified date | October 2022 |
Source | Ruijin Hospital |
Contact | Yuhui Shen, MD |
Phone | +86 13918209875 |
yuhuiss[@]163.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma
Status | Recruiting |
Enrollment | 41 |
Est. completion date | May 2024 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosed and histopathologically confirmed as high histologic grade soft-tissue sarcoma, including undifferentiated pleomorphic sarcoma (UPS), liposarcoma(LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), alveolar soft-part sarcoma (ASPS), clear cell sarcoma (CCS). 2. Upper limb (including shoulder), lower limb (including hip) and pelvic soft-tissue sarcoma, 3. Age = 18 years, 4. High risk of local recurrence was defined if the largest diameter of tumor >5cm and had at least one of below characters (1) Tumor border close (<5mm) to vital tissue (vessel and nerve) from diagnostic MRI (2) MRI shows infiltrative tumor grow type ('focal-type' and 'diffuse-type') (3) Positive microscopic margins or macroscopic residual (4) Recurrent tumor form previous treatment High risk of recurrence must be assessed by staff including a surgeon specialized in sarcoma, 5. Eastern Cooperative Oncology Group (ECOG) performance status = 2, 6. Only one lesion, and can be accurately measured at baseline as = 5cm in the longest diameter with magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements according to RECIST 1.1, 7. Adequate hematological, renal, metabolic and hepatic function: Haemoglobin = 9 g/dL and no blood transfusions in the 14 days prior to study entry Absolute neutrophil count (ANc) = 1.5 x 109/L Platelets = 100 x 109/L Total bilirubin = 1.5 x upper limit of normality (ULN), Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) = 2.5 x ULN, Serum creatinine = 150 µmol/L or creatinine clearance = 50 mL/min (according to local institution) in case of serum creatinine > 150 µmol/L, TP, INR = 1.5 x ULN 8. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up, 9. Voluntary signed and dated written informed consent prior to any specific procedure, 10. Patients have a life expectancy of more than 2 years with appropriate therapy, 11. All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met. Exclusion Criteria: 1. Any previous treatment, including chemotherapy, radiotherapy and target therapy, within 6 months from the last time prior to study treatment, 2. Soft-tissue sarcoma occurred at head and neck, visceral organs, retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis 3. Patients with the following entities were excluded: GIST, rhabdomyosarcoma, chondrosarcoma, osteosarcoma, dermatofibrosarcoma protuberans, Ewing sarcoma, primitive neuroectodermal tumor, inflammatory myofibroblastic tumor, and malignant mesothelioma. 4. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication, 5. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy, 6. Patients with known active hepatic disease (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids, 7. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease on HRCT scan or any psychiatric disorder that prohibits obtaining informed consent, 8. Patients with uncontrolled seizures, 9. Women of childbearing potential who are not using an effective method of contraception; women who are pregnant or breast feeding, 10. No prior or concurrent malignant disease diagnosed or treated in the last 2 years, 11. Resting ECG with QTc > 470msec on 2 or more time points within a 24 hour period or family history of long QT syndrome, 12. Blood transfusions within 14 days prior to study start, 13. Patients with myelodysplastic syndrome/acute myeloid leukaemia, 14. Major surgery within 6 months of starting study treatment and patients must have recovered from any effects of any major surgery, 15. Participation to a study involving a medical or therapeutic intervention in the last 3 months, 16. Patient unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons, 17. Previous enrollment in the present study, 18. Patients with a known hypersensitivity to study medicines or any of the excipients of the product, 19. Patients with metastasis. |
Country | Name | City | State |
---|---|---|---|
China | Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Ruijin Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Local Recurrence Free Survival (LRFS) | From the time of surgery to the time of local recurrence identified by image examination. | 36-month | |
Secondary | Metastasis free survival (MFS) | From the time of surgery to the time of metastasis identified by image examination. | 36-month | |
Secondary | Overall Survival (OS) | From the time of surgery to the time of death. | 36-month | |
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE_5.0 | an average of 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02910895 -
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)
|
N/A | |
Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
Active, not recruiting |
NCT04032964 -
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
|
Phase 1 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01650077 -
Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
|
||
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Completed |
NCT02204111 -
Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
|
||
Withdrawn |
NCT01663090 -
Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas
|
N/A | |
Completed |
NCT01440088 -
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
|
Phase 3 | |
Completed |
NCT01259375 -
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01106872 -
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
|
Phase 1 | |
Recruiting |
NCT00753727 -
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00755261 -
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
|
Phase 2 | |
Completed |
NCT00611078 -
Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study
|
N/A | |
Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT03452644 -
US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
|
||
Recruiting |
NCT05539677 -
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
|
||
Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 |